- Home
- NMT vs ARMP Comparison
NMT vs ARMP Comparison
Compare NMT & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMT
- ARMP
- Stock Information
- Founded
- NMT 1993
- ARMP N/A
- Country
- NMT United States
- ARMP United States
- Employees
- NMT N/A
- ARMP N/A
- Industry
- NMT Finance/Investors Services
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NMT Finance
- ARMP Health Care
- Exchange
- NMT Nasdaq
- ARMP Nasdaq
- Market Cap
- NMT 107.8M
- ARMP 125.7M
- IPO Year
- NMT N/A
- ARMP N/A
- Fundamental
- Price
- NMT $11.47
- ARMP $5.73
- Analyst Decision
- NMT
- ARMP Strong Buy
- Analyst Count
- NMT 0
- ARMP 1
- Target Price
- NMT N/A
- ARMP $9.00
- AVG Volume (30 Days)
- NMT 19.1K
- ARMP 759.0K
- Earning Date
- NMT 01-01-0001
- ARMP 11-07-2025
- Dividend Yield
- NMT 3.21%
- ARMP N/A
- EPS Growth
- NMT N/A
- ARMP N/A
- EPS
- NMT N/A
- ARMP N/A
- Revenue
- NMT N/A
- ARMP $6,868,000.00
- Revenue This Year
- NMT N/A
- ARMP $8.43
- Revenue Next Year
- NMT N/A
- ARMP N/A
- P/E Ratio
- NMT N/A
- ARMP N/A
- Revenue Growth
- NMT N/A
- ARMP 84.67
- 52 Week Low
- NMT $9.05
- ARMP $0.90
- 52 Week High
- NMT $10.93
- ARMP $16.34
- Technical
- Relative Strength Index (RSI)
- NMT 42.08
- ARMP 63.43
- Support Level
- NMT $11.42
- ARMP $4.65
- Resistance Level
- NMT $11.60
- ARMP $6.36
- Average True Range (ATR)
- NMT 0.09
- ARMP 1.34
- MACD
- NMT -0.01
- ARMP 0.01
- Stochastic Oscillator
- NMT 23.68
- ARMP 22.25
About NMT Nuveen Massachusetts Quality Municipal Income Fund
Nuveen Massachusetts Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's objective seeks to provide current income exempt from both regular federal and Massachusetts income taxes and to enhance portfolio value relative to the Massachusetts municipal bond market by investing in tax-exempt Massachusetts municipal obligations that are underrated or undervalued or that represent municipal market sectors that are undervalued.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.